Schering Corporation

Merck Sharp + Dohme Corp.

Other

Pharacopeia Drug Discovery, Inc.

Theodros Asberom

John W Clader

Samuel Chackalamannil

Hubert B Josien

Dmitri A Pissarnitski

Michael J Green

Joel G Berger

Derek B Lowe

Joseph A Kozlowski

Sundeep Dugar

Stuart W McCombie

Wayne D Vaccaro

Margaret H Sherlock

Wei K Chang

Wing C Tom

Susan F Vice

Ruo Xu

Allen Barnett

Robert D McQuade

Lian-Yong Chen

Margaret E Browne

Hongmei Li

Jayaram R Tagat

Duane A Burnett

Wen-Lian Wu

Wang Yuguang

Andrew William Stamford

Zhaoning Zhu

Xianhai Huang

Zhiqiang Zhao

Thavalakulamgara K Sasikumar

Yuguang Wang

Chad E Bennett

Mark D McBriar

William J Greenlee

Tao Guo

Elizabeth M Smith

Yan Xia

Craig D Boyle

Douglas Walsh Hobbs

Jing Su

Haiqun Tang

Martin C Clasby

Thomas A Bara

Michael F Czarniecki

Chad E Knutson

Martin Domalski

Li Qiang

Murali Rajagopalan

David James Cole

Dario Doller

Yueqing Hu

Jared N Cumming

Anandan Palani

Jack D Scott

Robert D Mazzola, Jr

Johannes H Voigt

Zhong-Yue Sun

Jun Qin

Xiaohong Zhu

Mary Ann Caplen

Gioconda V Gallo

Henry S Guzik

Thavalakulamgara K Sasiskumar

Javaram R Tagat

Mary Anne Caplen

Dimitri A Pissarntiski

Edward O'Connor

Chad Bennett

Martin S Domalski

Thomas Bara

Thavalakulamgar K Sasikumar

In its many embodiments, the present invention provides certain iminothiazine dioxide compounds, including compounds Formula (I): 

2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (Chemical formula should be inserted here as it appears on abstract in paper form). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

Gamma secretase modulators

Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L, n, X, Ar, Y, Z, Q, and Qare as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0. 

Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I). 

The present invention provides a novel class of heterocyclic compounds of Formula (I) as modulators of gamma secretase, wherein the definitions of the variables of Formula (I) are defined herein, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions. 

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

This invention discloses novel gamma secretase inhibitors of the formula: wherein:

Gamma secretase inhibitors

Novel aryl and heteroaryl sulfonamides are disclosed. The sulfonamides, which are gamma secretase inhibitors, are represented by the formula:wherein Arand Arindependently represent aryl or heteroaryl and Y represents a bond or a &#x2014;(C(R))group. Also disclosed is a method of inhibiting gamma secretase, and a method of treating Alzheimer's disease using the compounds of formula I.

A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.1), with the variables defined herein, which is useful for treating sexual dysfunction and other physiological disorders: A representative example is:

Polycyclic guanine phosphodiesterase V inhibitors

A compound having the formula (Ia) or (b), salt or solvate thereof, with the variables as defined herein, which can inhibit selectively phosphodiesterase V and can be useful for treating sexual dysfunction and other physiological disorders, symptoms and diseases:

Polycyclic guanine derivative phosphodiesterase V inhibitors

Muscarinic antagonists

Heterocyclic-substituted tricyclics of the formula

Thrombin receptor antagonists

Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates)

Growing community of inventors

West Orange, NJ, United States of America

Theodros Asberom